Paul Chang has over 18 years of experience in drug development. He was worked for both large pharmaceutical and small biotechnology companies, managing teams and executing complex global clinical programs across multiple therapeutic areas. He has held roles of increasing responsibilities while at Gilead Sciences Inc. and Amgen Inc. where he led and managed the clinical operations teams for the approvals of Harvoni® (ledipasivir/sofosbuvir) and Nplate® (romiplostim). He served as the Head of Clinical Operations at CymaBay Therapeutics where he led the clinical operations team and oversaw of the company’s liver and other chronic disease programs for seladelpar. Prior to joining NKGen Biotech, Paul was the Vice President, Clinical Operations at DNAtrix, Inc. managing and building teams across multiple departments preparing to launch a Phase 3 program for glioblastoma with tasadenoturev.
Paul received his Master of Public Health from Loma Linda University and his Bachelor of Science in Biology with a Specialization in Business and Administration from the University of California, Los Angeles.